# üéñÔ∏è GENERAL'S BATTLE MAP: Strategic Intelligence Framework

**Date:** January 28, 2025  
**Purpose:** Connect all CrisPRO capabilities into a unified strategic intelligence framework  
**Status:** üß† **STRATEGIC THINKING** - Connecting the dots

---

## üéØ THE STRATEGIC VISION

**What We're Building:**
A Command & Control system that tells CrisPRO agents:
- **WHAT tests exist** (the intelligence sources)
- **WHAT each test reveals** (the signals)
- **HOW to interpret changes over time** (the patterns)
- **WHAT actions to trigger** (the decisions)

This is **COMMAND & CONTROL for cancer warfare**.

---

## üîó CONNECTING THE DOTS: Our Work ‚Üí The 6 Pillars

### **PILLAR 1: TUMOR BURDEN** ‚Üí What We've Built

**What It Tracks:** How much cancer exists (shrinking vs growing)

**Our Capabilities:**
1. ‚úÖ **Biomarker Intelligence (Universal)**
   - CA-125 tracking (ovarian) - burden classification, response forecast
   - CEA tracking (colorectal, pancreatic) - doubling time calculation
   - PSA tracking (prostate) - velocity calculation
   - Trend analysis over time

2. ‚úÖ **CA-125 Intelligence Service**
   - Burden thresholds: MINIMAL/MODERATE/SIGNIFICANT/EXTENSIVE
   - Response expectations: cycle 3 (70% drop), cycle 6 (90% drop)
   - Resistance signals: <50% drop by cycle 3 ‚Üí resistance signal

3. ‚úÖ **Trigger System**
   - CA-125 > baseline * 1.25 ‚Üí resistance_detected trigger
   - Rising CA-125 after nadir ‚Üí trigger ctDNA sequencing
   - Doubling time <90 days ‚Üí URGENT escalation

4. ‚úÖ **State Management**
   - Historical CA-125 values tracked
   - Baseline recorded
   - Trend analysis enabled

**What's Missing:**
- ‚ùå Imaging-based tumor burden (CT/PET RECIST criteria) - not yet integrated
- ‚ùå ctDNA tumor fraction tracking - partially built (ctDNA exists but tumor fraction not explicitly tracked)
- ‚ùå CTC count tracking - not built

**Connection Point:**
```
CA-125 Test ‚Üí Biomarker Intelligence ‚Üí Trigger System ‚Üí Actions
  ‚Üì
Pattern: Rising after nadir ‚Üí Resistance signal
  ‚Üì
Action: Order ctDNA, search trials, escalate to tumor board
```

---

### **PILLAR 2: GENOMIC EVOLUTION** ‚Üí What We've Built

**What It Tracks:** What mutations are driving cancer NOW (resistance mechanisms, new vulnerabilities)

**Our Capabilities:**
1. ‚úÖ **Resistance Prediction (Resistance Prophet)**
   - Detects resistance mutations: DIS3 (RR=2.08), NF1 (RR=2.10), MAPK pathway (RR=1.97)
   - Validated on real cohorts (MMRF, TCGA)
   - Provides alternatives: carfilzomib, daratumumab, olaparib, trametinib
   - Downstream handoffs: drug_efficacy, care_plan, monitoring

2. ‚úÖ **Drug Efficacy (S/P/E Framework)**
   - Identifies vulnerabilities: DDR-high ‚Üí PARP inhibitors
   - Pathway disruption scores: {"ddr": 0.88, "ras_mapk": 0.12, ...}
   - Mechanism vector: [DDR, MAPK, PI3K, VEGF, HER2, IO, Efflux]
   - 100% pathway alignment accuracy (MM)

3. ‚úÖ **Mechanism-Based Trial Matching**
   - Matches trials to vulnerabilities: DDR-high ‚Üí PARP+ATR trials (0.92 mechanism fit)
   - Mechanism alignment breakdown per pathway
   - Combined scoring: 0.7√óeligibility + 0.3√ómechanism_fit

4. ‚úÖ **Next Test Recommender**
   - Prioritizes genomic tests: HRD ‚Üí ctDNA ‚Üí SLFN11 ‚Üí ABCB1
   - Differential branches: "If HRD ‚â•42 ‚Üí PARP eligible; If <42 ‚Üí consider ATR trials"
   - Turnaround times and cost estimates

5. ‚úÖ **Trigger System**
   - New mutations in ctDNA ‚Üí clonal_evolution trigger
   - Rising VAF ‚Üí molecular_progression trigger
   - Pathway changes ‚Üí pathway_escape trigger

6. ‚úÖ **State Management**
   - Historical pathway burden tracked: DDR 0.88 ‚Üí 0.73 ‚Üí 0.65 (resistance signal)
   - Mechanism vector changes over time
   - Mutation evolution tracked

**What's Missing:**
- ‚ùå ctDNA VAF tracking over time - partially built (ctDNA exists but VAF trends not explicitly tracked)
- ‚ùå Clonal evolution detection - not built (would need mutation comparison over time)
- ‚ùå New mutation detection in ctDNA - not built (would need baseline comparison)

**Connection Point:**
```
ctDNA Test ‚Üí Resistance Prediction ‚Üí Drug Efficacy ‚Üí Trial Matching
  ‚Üì
Pattern: New TP53 mutation + DDR pathway drop ‚Üí Resistance emerging
  ‚Üì
Action: Re-rank drugs, search salvage trials, update care plan
```

---

### **PILLAR 3: IMMUNE STATUS** ‚Üí What We've Built

**What It Tracks:** Is the immune system fighting or exhausted? (IO eligibility)

**Our Capabilities:**
1. ‚úÖ **Biomarker Intelligence (Universal)**
   - TMB calculation and tracking
   - MSI status detection (MSI-H, MSS)
   - HRD score tracking
   - IO eligibility determination: TMB ‚â•10 OR MSI-H ‚Üí IO eligible

2. ‚úÖ **Trigger System**
   - TMB ‚â•10.0 ‚Üí tmb_high_detected trigger
   - MSI-H ‚Üí msi_high_detected trigger
   - HRD ‚â•42 ‚Üí hrd_score_received trigger
   - Actions: update_io_eligibility, re_rank_drugs, match_io_trials

3. ‚úÖ **Drug Efficacy (S/P/E Framework)**
   - IO index in mechanism vector: IO = 1.0 if TMB ‚â•20 OR MSI-High
   - IO-eligible patients get checkpoint inhibitors ranked higher

4. ‚úÖ **Trial Matching**
   - IO-eligible patients matched to checkpoint inhibitor trials
   - Mechanism fit for IO pathway

**What's Missing:**
- ‚ùå PD-L1 expression tracking - not built
- ‚ùå TIL (tumor-infiltrating lymphocytes) analysis - not built
- ‚ùå Exhaustion markers (PD-1, TIM-3, LAG-3) - not built

**Connection Point:**
```
TMB Test ‚Üí Biomarker Intelligence ‚Üí Trigger System ‚Üí Drug Efficacy
  ‚Üì
Pattern: TMB ‚â•10 ‚Üí IO eligible
  ‚Üì
Action: Boost checkpoint inhibitors in drug ranking, match IO trials
```

---

### **PILLAR 4: METABOLIC STATE** ‚Üí What We Haven't Built

**What It Tracks:** What fuel is the tumor using? (glucose, glutamine, lactate)

**Our Capabilities:**
- ‚ùå **Not Built Yet** - This is a new domain

**What Could Be Built:**
- PET-CT SUV max tracking (metabolic activity)
- Glucose/glutamine dependency analysis
- Lactate production tracking
- Metabolic pathway vulnerabilities (IDH mutations, etc.)

**Connection Point (Future):**
```
PET-CT Test ‚Üí Metabolic Analysis ‚Üí Drug Efficacy (metabolic inhibitors)
  ‚Üì
Pattern: High SUV despite stable size ‚Üí Metabolically active resistance
  ‚Üì
Action: Consider metabolic inhibitors, escalate therapy
```

---

### **PILLAR 5: MICROENVIRONMENT** ‚Üí What We Haven't Built

**What It Tracks:** What's protecting the tumor? (hypoxia, fibrosis, suppressive cells)

**Our Capabilities:**
- ‚ùå **Not Built Yet** - This is a new domain

**What Could Be Built:**
- Hypoxia markers (HIF-1Œ±)
- Fibrosis markers (collagen, TGF-Œ≤)
- Treg/MDSC counts (suppressive immune cells)
- Angiogenesis markers (VEGF)

**Connection Point (Future):**
```
Microenvironment Test ‚Üí Pathway Analysis ‚Üí Drug Efficacy (anti-angiogenic)
  ‚Üì
Pattern: High VEGF + hypoxia ‚Üí Aggressive microenvironment
  ‚Üì
Action: Consider bevacizumab, anti-angiogenic trials
```

---

### **PILLAR 6: TOXICITY/TOLERANCE** ‚Üí What We've Partially Built

**What It Tracks:** Can the patient handle more therapy? (side effects, dose adjustments)

**Our Capabilities:**
1. ‚úÖ **Pharmacogenomics (PGx)**
   - DPYD variants ‚Üí 5-FU toxicity risk
   - UGT1A1 variants ‚Üí irinotecan toxicity risk
   - CYP2D6 variants ‚Üí tamoxifen metabolism

2. ‚úÖ **Trigger System**
   - PGx variant detected ‚Üí toxicity_risk trigger
   - Adverse event (CTCAE ‚â•2) ‚Üí adverse_event_reported trigger
   - Actions: suggest_supportive_care, escalate if grade ‚â•3

**What's Missing:**
- ‚ùå Comprehensive toxicity tracking - partially built
- ‚ùå Dose adjustment recommendations - not built
- ‚ùå Supportive care recommendations - not built

**Connection Point:**
```
PGx Test ‚Üí Toxicity Risk ‚Üí Trigger System ‚Üí Care Plan
  ‚Üì
Pattern: DPYD variant detected ‚Üí 5-FU toxicity risk
  ‚Üì
Action: Avoid 5-FU, suggest alternative, adjust dose
```

---

## üéØ THE STRATEGIC INTELLIGENCE FLOW

### **How Tests ‚Üí Signals ‚Üí Patterns ‚Üí Actions**

```
1. TEST UPLOADED
   ‚Üì
2. BIOMARKER INTELLIGENCE (Pillar 1: Tumor Burden)
   - CA-125: 2,842 ‚Üí 1,200 ‚Üí 800 ‚Üí 1,500 (rising after nadir)
   - Pattern: Resistance emerging
   ‚Üì
3. TRIGGER SYSTEM DETECTS
   - Condition: CA-125 > baseline * 1.25
   - Severity: HIGH
   ‚Üì
4. AUTOMATED ACTIONS
   - Order ctDNA sequencing (Next Test Recommender)
   - Run resistance analysis (Resistance Prediction)
   - Re-rank drugs (Drug Efficacy)
   - Search salvage trials (Trial Matching)
   - Notify oncologist
   ‚Üì
5. CTDNA RESULTS (Pillar 2: Genomic Evolution)
   - New TP53 mutation detected
   - DDR pathway burden: 0.88 ‚Üí 0.65 (dropping)
   - Pattern: Clonal evolution, resistance mechanism
   ‚Üì
6. UPDATED ACTIONS
   - Drug Efficacy: Re-rank (avoid current drug, prioritize alternatives)
   - Trial Matching: Search PARP+ATR salvage trials
   - Care Plan: Update regimen
   - Monitoring: Increase frequency
```

---

## üîó EXISTING CONNECTIONS (What We've Built)

### **1. Biomarker Intelligence ‚Üí Trigger System ‚Üí Actions**
- ‚úÖ CA-125 rise ‚Üí resistance_detected trigger ‚Üí ctDNA order + trial search
- ‚úÖ TMB ‚â•10 ‚Üí tmb_high_detected trigger ‚Üí IO eligibility + IO trials
- ‚úÖ MSI-H ‚Üí msi_high_detected trigger ‚Üí IO eligibility + Lynch screening

### **2. Resistance Prediction ‚Üí Drug Efficacy ‚Üí Trial Matching**
- ‚úÖ DIS3 detected ‚Üí alternatives (carfilzomib, daratumumab) ‚Üí drug_efficacy handoff
- ‚úÖ NF1 detected ‚Üí alternatives (olaparib, trametinib) ‚Üí drug_efficacy handoff
- ‚úÖ Mechanism vector extracted from drug efficacy ‚Üí trial matching with mechanism fit

### **3. Next Test Recommender ‚Üí State Management ‚Üí Pattern Recognition**
- ‚úÖ HRD missing ‚Üí recommend HRD test ‚Üí track HRD score over time
- ‚úÖ ctDNA missing ‚Üí recommend ctDNA ‚Üí track mutations over time
- ‚úÖ Historical tracking enables pattern recognition (pathway changes, resistance signals)

### **4. Trigger System ‚Üí State Management ‚Üí Historical Analysis**
- ‚úÖ CA-125 trends tracked ‚Üí baseline comparison ‚Üí resistance detection
- ‚úÖ Pathway burden tracked: DDR 0.88 ‚Üí 0.73 ‚Üí 0.65 ‚Üí resistance signal
- ‚úÖ Mechanism vector changes tracked ‚Üí pathway escape detection

---

## üéØ WHAT'S MISSING (Gaps to Fill)

### **Pillar 1: Tumor Burden**
- ‚ùå Imaging-based burden (CT/PET RECIST) - not integrated
- ‚ùå ctDNA tumor fraction tracking - partially built
- ‚ùå CTC count tracking - not built

### **Pillar 2: Genomic Evolution**
- ‚ùå ctDNA VAF trends over time - partially built
- ‚ùå Clonal evolution detection - not built
- ‚ùå New mutation detection in ctDNA - not built

### **Pillar 3: Immune Status**
- ‚úÖ **MOSTLY COMPLETE** - TMB, MSI, HRD tracked
- ‚ùå PD-L1 expression - not built
- ‚ùå TIL analysis - not built

### **Pillar 4: Metabolic State**
- ‚ùå **NOT BUILT** - New domain

### **Pillar 5: Microenvironment**
- ‚ùå **NOT BUILT** - New domain

### **Pillar 6: Toxicity/Tolerance**
- ‚ö†Ô∏è **PARTIALLY BUILT** - PGx exists, but comprehensive toxicity tracking missing

---

## üéñÔ∏è THE STRATEGIC FRAMEWORK (How to Build It)

### **Phase 1: Catalog All Tests (Intelligence Sources)**

**What We Need:**
1. **Test Registry** - Every test that exists, what it measures, which pillar(s) it maps to
2. **Signal Extraction** - What signals each test reveals (CA-125 ‚Üí tumor burden, ctDNA ‚Üí genomic evolution)
3. **Pattern Recognition** - How to interpret changes over time (rising CA-125 ‚Üí resistance, new mutations ‚Üí clonal evolution)
4. **Action Triggers** - What actions to take based on patterns (resistance ‚Üí order ctDNA, search trials)

**Our Starting Point:**
- ‚úÖ CA-125 Intelligence (burden, response, resistance)
- ‚úÖ Resistance Prediction (DIS3, NF1, MAPK)
- ‚úÖ Next Test Recommender (HRD, ctDNA, SLFN11, ABCB1)
- ‚úÖ Trigger System (resistance_detected, tmb_high_detected, etc.)

### **Phase 2: Map Tests to Pillars**

**What We Need:**
1. **Test ‚Üí Pillar Mapping** - Which tests inform which pillars
2. **Multi-Pillar Tests** - Tests that inform multiple pillars (ctDNA ‚Üí Tumor Burden + Genomic Evolution)
3. **Pillar Coverage** - Which pillars are well-covered vs. gaps

**Our Current State:**
- ‚úÖ Pillar 1 (Tumor Burden): CA-125, CEA, PSA - **GOOD COVERAGE**
- ‚úÖ Pillar 2 (Genomic Evolution): Resistance Prediction, Drug Efficacy, ctDNA - **GOOD COVERAGE**
- ‚úÖ Pillar 3 (Immune Status): TMB, MSI, HRD - **GOOD COVERAGE**
- ‚ùå Pillar 4 (Metabolic): **NO COVERAGE**
- ‚ùå Pillar 5 (Microenvironment): **NO COVERAGE**
- ‚ö†Ô∏è Pillar 6 (Toxicity): PGx - **PARTIAL COVERAGE**

### **Phase 3: Pattern Recognition (Time-Based Intelligence)**

**What We Need:**
1. **Baseline Establishment** - Record baseline values (CA-125 baseline, pathway burden baseline)
2. **Trend Analysis** - Track changes over time (CA-125: 2,842 ‚Üí 1,200 ‚Üí 800 ‚Üí 1,500)
3. **Pattern Detection** - Identify patterns (rising after nadir ‚Üí resistance, pathway drop ‚Üí escape)
4. **Predictive Signals** - Early warning signs (molecular progression before imaging)

**Our Current State:**
- ‚úÖ State Management tracks historical values
- ‚úÖ CA-125 Intelligence has trend analysis (doubling time, velocity)
- ‚úÖ Trigger System detects patterns (CA-125 > baseline * 1.25)
- ‚ö†Ô∏è **NEEDS ENHANCEMENT** - More comprehensive pattern recognition

### **Phase 4: Action Triggers (Decision Framework)**

**What We Need:**
1. **Trigger Conditions** - When to trigger actions (CA-125 rise, new mutations, TMB-H)
2. **Action Catalog** - What actions to take (order ctDNA, search trials, escalate)
3. **Escalation Rules** - When to escalate (24h no response ‚Üí tumor board)
4. **Priority Logic** - Which actions take priority (resistance > routine monitoring)

**Our Current State:**
- ‚úÖ Trigger System exists with conditions and actions
- ‚úÖ Downstream handoffs (drug_efficacy, care_plan, monitoring)
- ‚úÖ Escalation rules (24h ‚Üí tumor board)
- ‚ö†Ô∏è **NEEDS ENHANCEMENT** - More comprehensive action catalog

---

## üéØ THE STRATEGIC INTELLIGENCE FRAMEWORK (How It Works)

### **Example: CA-125 Rising After Nadir**

```
1. TEST: CA-125 = 1,500 (was 800 at nadir)
   ‚Üì
2. PILLAR: Tumor Burden (Pillar 1)
   ‚Üì
3. SIGNAL: Rising after nadir (2x consecutive rise)
   ‚Üì
4. PATTERN: Resistance emerging (doubling time <90 days)
   ‚Üì
5. TRIGGER: resistance_detected (HIGH severity)
   ‚Üì
6. ACTIONS:
   - Order ctDNA sequencing (Next Test Recommender)
   - Run resistance analysis (Resistance Prediction)
   - Re-rank drugs (Drug Efficacy - avoid current, prioritize alternatives)
   - Search salvage trials (Trial Matching - mechanism-aligned)
   - Notify oncologist
   - Escalate to tumor board if no response in 24h
```

### **Example: New TP53 Mutation in ctDNA**

```
1. TEST: ctDNA shows new TP53 mutation (not in baseline)
   ‚Üì
2. PILLAR: Genomic Evolution (Pillar 2)
   ‚Üì
3. SIGNAL: New mutation detected (clonal evolution)
   ‚Üì
4. PATTERN: Resistance mechanism emerging (TP53 ‚Üí checkpoint bypass)
   ‚Üì
5. TRIGGER: clonal_evolution (HIGH severity)
   ‚Üì
6. ACTIONS:
   - Update resistance prediction (Resistance Prediction)
   - Re-rank drugs (Drug Efficacy - account for new mutation)
   - Search trials targeting TP53 (Trial Matching)
   - Update care plan (Care Plan - new regimen)
   - Increase monitoring frequency (Monitoring)
```

### **Example: TMB-High Detected**

```
1. TEST: TMB = 15.2 mut/Mb
   ‚Üì
2. PILLAR: Immune Status (Pillar 3)
   ‚Üì
3. SIGNAL: TMB ‚â•10 (TMB-High)
   ‚Üì
4. PATTERN: IO eligible (new treatment option unlocked)
   ‚Üì
5. TRIGGER: tmb_high_detected (MEDIUM severity)
   ‚Üì
6. ACTIONS:
   - Update IO eligibility (Biomarker Intelligence)
   - Re-rank drugs (Drug Efficacy - boost checkpoint inhibitors)
   - Match IO trials (Trial Matching - mechanism fit for IO pathway)
   - Notify oncologist
```

---

## üéñÔ∏è THE STRATEGIC FRAMEWORK (What We Need to Build)

### **1. Test Registry (Intelligence Sources)**

**Structure:**
```yaml
TESTS:
  ca125:
    pillar: [tumor_burden]
    signals: [absolute_value, trend, doubling_time, velocity]
    patterns:
      - rising_after_nadir: resistance_emerging
      - doubling_time_<90d: aggressive_progression
    actions:
      - if_rising: order_ctdna, search_trials, escalate
      
  ctdna:
    pillar: [tumor_burden, genomic_evolution]
    signals: [vaf, tumor_fraction, new_mutations, clonal_evolution]
    patterns:
      - rising_vaf: molecular_progression
      - new_mutations: clonal_evolution
    actions:
      - if_new_mutations: update_resistance, re_rank_drugs, search_trials
      
  tmb:
    pillar: [immune_status]
    signals: [absolute_value, io_eligibility]
    patterns:
      - tmb_>=10: io_eligible
    actions:
      - if_io_eligible: boost_checkpoint_inhibitors, match_io_trials
```

### **2. Pattern Recognition Engine**

**Structure:**
```yaml
PATTERNS:
  resistance_emerging:
    conditions:
      - ca125_rising_after_nadir
      - pathway_burden_dropping
      - new_mutations_in_ctdna
    confidence: high
    actions: [order_ctdna, search_trials, escalate]
    
  molecular_progression:
    conditions:
      - rising_vaf_in_ctdna
      - new_driver_mutations
    confidence: medium
    actions: [update_resistance, re_rank_drugs]
    
  io_eligible:
    conditions:
      - tmb_>=10 OR msi_high
    confidence: high
    actions: [boost_checkpoint_inhibitors, match_io_trials]
```

### **3. Action Catalog (Decision Framework)**

**Structure:**
```yaml
ACTIONS:
  order_ctdna:
    trigger: resistance_emerging
    priority: high
    turnaround: 7d
    cost: $3,000-$5,000
    
  search_trials:
    trigger: resistance_emerging OR new_mutations
    priority: high
    mechanism_fit: true
    max_results: 10
    
  re_rank_drugs:
    trigger: resistance_emerging OR new_mutations
    priority: high
    exclude: current_drug
    prioritize: mechanism_fit
```

---

## üéØ THE STRATEGIC VISION (What This Enables)

### **For Clinicians:**
- **Complete Intelligence Picture** - See all tests, signals, patterns, actions in one place
- **Early Warning System** - Detect resistance before imaging shows progression
- **Automated Decision Support** - Actions triggered automatically based on patterns
- **Historical Context** - See how patient's cancer has evolved over time

### **For Patients:**
- **Personalized Monitoring** - Tests ordered based on their specific cancer type and mutations
- **Faster Response** - Early detection of resistance ‚Üí faster treatment switch
- **Better Outcomes** - Mechanism-aligned treatment ‚Üí higher response rates

### **For CrisPRO Agents:**
- **Clear Intelligence Sources** - Know what tests exist and what they reveal
- **Pattern Recognition** - Understand how to interpret changes over time
- **Action Triggers** - Know what actions to take based on patterns
- **Strategic Coordination** - All agents work from the same intelligence framework

---

## üéñÔ∏è NEXT STEPS (How to Build This)

### **Phase 1: Catalog All Tests (1-2 weeks)**
1. List all tests we currently support (CA-125, CEA, PSA, TMB, MSI, HRD, ctDNA, etc.)
2. Map each test to pillar(s)
3. Document what signals each test reveals
4. Document what patterns to look for

### **Phase 2: Pattern Recognition Engine (2-3 weeks)**
1. Build pattern detection logic (rising CA-125, new mutations, pathway changes)
2. Integrate with State Management for historical tracking
3. Build confidence scoring for patterns
4. Test with real patient data

### **Phase 3: Action Catalog (1-2 weeks)**
1. Catalog all possible actions (order tests, search trials, re-rank drugs, escalate)
2. Map actions to triggers
3. Build priority logic
4. Integrate with existing trigger system

### **Phase 4: Strategic Dashboard (2-3 weeks)**
1. Build unified view of all 6 pillars
2. Show test results, signals, patterns, actions
3. Historical timeline view
4. Predictive signals (early warnings)

---

*Document Author: Zo (Strategic Thinking)*  
*Last Updated: January 28, 2025*  
*Status: üß† STRATEGIC FRAMEWORK - Connecting the dots*


